Dr. Gerhard Bauer-Lewerenz
Bauer-Lewerenz Consulting
Referent:innen
Torsten Kneuss
Bayer
Lee Wood
Medical Human Factors
Dr Daniel Meier
confinis
Steve Augustyn
Cambridge Design Partnership
Note: All times mentioned are CET.
Zielsetzung
This Live Online Course provides a comprehensive overview of the technical and regulatory requirements for the Development and maintenance of drug-device combination products (with a focus on EU & US).
Participants will learn and understand
- the basics – distinctions between drugs, devices and ‘combination products’,
- the current applicable regulations, standards and guidelines related to the design and development of combination products and how to be compliant with those requirements
- the key elements of Design Controls, Risk Management and Usability Engineering.
Case Studies are an integral part of the course Programme.
Hintergrund
More than half of the TOP20 drug products on the market include at least one device constituent part and are therefore considered drug-device combination products. Drug-Device combination products are specifically regulated in the US. However, there is also an increasing oversight by regulatory authorities in the EU. GMP compliant development and life-cycle Management are, therefore, essential for obtaining and maintain a Marketing authorization for such products.
What is a Combination Product?
“Combination Product”, as per 21 CFR Part 3.2(e), is a term defined by the FDA to cover products which consist of two or more components (i.e., drug, biologic, device) regulated under different regulations. The FDA differentiates between three Basic types of combination products:
- Single-entity combination products,
- Co-packaged combination products,
- Cross-labeled combination products.
Beyond these basic types also combinations of those basic types
are possible.
are possible.
During the past years, FDA established regulations and guidances for Combination Products, which further clarify what Combination Products are and which rules apply to such combinations.
21 CFR Part 4, along with the final guidance “Current Good Manufacturing Practice (cGMP) Requirements for Combination Products”, provides guidance on applicable quality requirements for combination products.
One essential requirement is to apply Design Controls as defined in 21 CFR Part 820.30 to the combination product as a whole. Design Controls are a set of quality practices and procedures to control the design process to assure that the combination product meets the user needs, intended uses and specified requirements. Design Controls are in different extent described in ISO 13485 (applicable for Medical Devices), in ISO 15378 (applicable to primary packaging materials) and even in the general Standard for Quality Management System ISO 9001.
In the EU, so far, there has been no equivalent term to “Combination Product”, a product is either considered a Medical Device or a Medicinal Product. Medical Devices have to comply with the EU Medical Device Regulation (MDR). Even though the term Combination Product does not exist, also in EU, the Design Controls apply to the so-called single-integral products, which are similar to single-entity combination products as defined in the US.
Also shared in EU and US is the requirement to apply Risk Management to those products. The respective standard ISO 14971 has been revised in 2019. The course will consider the current standard and provides guidance on how to apply Risk Management to drug-device combination products.
And lastly, also Usability Engineering, also known as Human Factors Engineering, needs to be considered in the Design and Development of combination products. The recent increase in Attention to this topic has brought many manufacturers into difficulties as they aim to prove high levels of intuitive use, use
safety and efficacy of the drug delivery system as a whole - for a Combination Product it is no longer just about the drug. Again, regulation, directives, guidance, standards and review expectations continue to evolve in this area.
safety and efficacy of the drug delivery system as a whole - for a Combination Product it is no longer just about the drug. Again, regulation, directives, guidance, standards and review expectations continue to evolve in this area.
This course focuses on design controls as applicable to various combinations of drugs and biologics with devices. The course intends to set a solid basic understanding of the application on Design Controls as well as on the topics of Risk Management and Usability Engineering. Beyond the basic understanding, the
course also aims to offer some practical experiences with the different elements to be considered.
course also aims to offer some practical experiences with the different elements to be considered.
Zielgruppe
This Live Online Course is designed for all scientists, engineers, managers and executives from Pharmaceutical and Biotech Development Units, including Device Development, Packaging Development, Quality Assurance, Regulatory Affairs, Marketing, and Project Management, who are involved in the development, industrialization and control of Drug-Device Combination Products.
Technical Requirements
We use Webex for our live online training courses and webinars. At www.gmp-compliance.org/training/online-training-technical-information you will find all the information you need to participate in our events and you can check if your system meets the necessary requirements to participate. If the installation of browser extensions is not possible due to your rights in the IT system, please contact your IT department. Webex is a standard nowadays and the necessary installation is fast and easy.
Programm
Gesamtes Programm als PDF herunterladen
Programme Day 1
Design Controls – An Introduction
- What are Design Controls?
- Purpose of Design Controls / Usability Engineering / Risk Management
- Drug Development vs. Device Development vs. Combination Product Development
- Terminology (e.g. DHF)
Design Planning and Design Review
- Definition of development scope / scope of Design Control
- Other planning activities
- Design Review Requirements
FDA Regulatory Expectations on Drug-Device Combinations
- Types of Combination Products and impact on GMP Requirements
- Which Medical Device Quality Systems are required and at which facilities are they required to be implemented?
- Expectations for Clinical Phases and for Submissions
- Post Marketing expectations
EU Requirements for Drug-Device Combinations
- Applicable EU regulations and guidances for Drug-Device Combinations
- Requirements for Single-Integral Products
- Setup of technical documentation
- Notified Body Opinion process
Q&A Session 1
Introduction to Risk Management
- ISO 14971: Terms/definitions, process, relevance for design controls
- EU and US requirements
- Determine Known Use Problems
Design Input
- From user needs and other stakeholder needs to design Input
- How to integrate results from UE, RM
- How to ensure „open-ended“ Development
- Requirements for engineering techniques
Case Study I: Risk Management (Example)
- Documentation of Risk Management activities / Risk Management File
- Update of risk management during Development
- Preparation of post-market surveillance (PMS) / PMS planning
Q&A Session 2
Programme Day 2
Design Output
- Development activities
- Definition of Design Outputs (Specifications)
- Quality Control Strategy
Introduction to Usability Engineering
- Introduction to IEC 62366-1
- How to determine user needs, user preference, use specification etc.
- US Guidances
Design Verification
- Design verification activities
- How to consider verification during design Input
- What to do if verification fails?
- Requirements for test methods and for use of statistical techniques
Design Transfer
- Design Transfer – Why and how?
- Device Master Record setup
Q&A Session 3
Design Validation / Usability Engineering Part 2
- Design Validation approaches
- Planning, setup and conduct of Summative studies
- Documentation of the UE activities / UEF
- HF/UE Report as required by FDA
Design Changes
- Design Change Control
- How to implement Design Change Control in Pharma
Case Study II: Development of an Auto-Injector
- Design Control, Risk Management and Usability Engineering aspects
- Setup of a technical documentation for Notified Body opinion
Q&A Session 4
| ECA-Member*: | € 1690,- |
| Non ECA Member*: | € 1890,- |
| EU/GMP Inspectorates*: | € 945,- |
| APIC Member Discount*: | € 1790,- |
Alle Preise zzgl. MwSt. Wichtige Hinweise zur Umsatzsteuer.
* auch unkompliziert per Kreditkarte bezahlbar
Weitere Termine vor Ort
Weitere Termine vor Ort nicht verfügbar
Weitere Termine online
Weitere Termine online nicht verfügbar
Aufzeichnung nicht verfügbar
This course is part of the GMP Certification Programme "ECA Certified Packaging Manager"
Haben Sie noch Fragen?
Wir stehen Ihnen für weitere Auskünfte gerne zur Verfügung.
E-Mail: info@concept-heidelberg.de
Teilnehmerstimmen
Seminarprogramm als PDF
Sonderkonditionen DB BahnTeilnehmerstimmen - das sagen andere über unsere Seminare:
